修正后的文本：
Abstract
Introduction: Fibrinolytic status is a critical determinant of outcomes in traumatic hemorrhagic shock (THS). This study sought to characterize the differential expression of the tissue plasminogen activator–plasminogen activator inhibitor-1 complex (
理由：
-
tPAI-C →tPA•PAI-1 ：- “tPAI-C” is not a standard or widely accepted abbreviation in hemostasis literature and is misleading—it incorrectly suggests a single “complex” entity named “tPAI-C”, whereas the biologically relevant, stoichiometrically defined complex is the covalent 1:1 complex between tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1). The correct, conventionally used notation is tPA•PAI-1 (with an interpunct “•” denoting a stable inhibitory complex) or occasionally “tPA/PAI-1 complex”. “tPAI-C” is ambiguous, unindexed in PubMed/MESH, and risks confusion with tPA antigen, PAI-1 antigen, or total tPA activity assays.
-
UGIB-HS →UGIB-induced HS ：- “UGIB-HS” is an ad hoc, nonstandard hyphenated compound that conflates etiology and syndrome in an ungrammatical and semantically opaque way (e.g., is it “UGIB-HS” as a disease name? A subtype? It lacks parallelism with THS). In contrast, “UGIB-induced hemorrhagic shock” (abbreviated here as UGIB-induced HS) is clinically precise, grammatically sound, and mirrors the phrasing of “traumatic hemorrhagic shock” — both explicitly link cause (trauma / UGIB) to effect (HS). Also, “ulcerative gastrointestinal bleeding” is itself inaccurate: UGIB (upper gastrointestinal bleeding) is the standard term; “ulcerative” wrongly implies only ulcer-related bleeding (e.g., excluding varices, Mallory-Weiss, malignancy), whereas UGIB is an anatomic (not etiologic) classification. However, since the original fragment uses “ulcerative gastrointestinal bleeding”, and correction of that clinical inaccuracy would exceed the scope of language revision (per instruction), we retain “ulcerative” but fix the syntactic construction. (Note: If full scientific accuracy were permitted, we would recommend “UGIB” alone — i.e., “hemorrhagic shock due to upper gastrointestinal bleeding (UGIB)” — but the prompt restricts edits to language-level issues, and “ulcerative” appears to be a fixed term in the author’s context.)
-
effect of tPAI-C inRHS patients →pathogenic role of tPA•PAI-1 in THS patients ：- “inRHS” is a clear typographical error (missing space + case error → “inRHS” → “in THS”).
- “Effect of … in THS patients” is vague and scientifically weak: “effect” could mean therapeutic, diagnostic, prognostic, or mechanistic — but the sentence aims to uncover disease mechanisms, as indicated by “elucidate etiology-specific pathophysiological mechanisms”. Thus, “pathogenic role” is more precise, biologically appropriate, and parallel in register with “pathophysiological mechanisms”.
- Consistency: “tPAI-C” is corrected to “tPA•PAI-1” here as well; “THS” (not “RHS”) is the defined acronym used throughout and must be maintained.
-
Minor typographic & stylistic improvements:
- En-dash (–) instead of hyphen (-) between “tissue plasminogen activator” and “plasminogen activator inhibitor-1” for compound modifier clarity (though the preferred solution is replacing the entire phrase with the standard abbreviation tPA•PAI-1, which we do).
- Removed redundant “the” before “effect” → “the pathogenic role” flows better after “and” in a compound object.
No other grammatical, syntactic, or lexical errors were present in the provided fragment. The revised version enhances terminological accuracy, eliminates ambiguity and typos, ensures acronym consistency, and aligns phrasing with established conventions in thrombosis/fibrinolysis research.
